CD30L, a type II membrane protein, is a member of the TNF superfamily. The extracellular domain of CD30L contains two cysteine residues that is unique within the family and may form inter-subunit disulfide linkage.
Interacting protein(s): CD-30
Related products: Hexa-Ligand
Read all details below including Quick Specs.
** Please note: For orders over 1 mg, please inquire here
|Synonym:||CD153, TNFSF8, CD30LG, MGC138144|
|Tag:||Mouse IgG2a Fc|
|Construction:||Mouse IgG2a Fc-Human CD30L (Q63-D234)|
|MW (calculated):||46,290 daltons|
|MW (SDS-PAGE)||50 Kd|
|Abs 0.1% (= 1 mg/ml):||1.18|
CD30L, a type II membrane protein, is a member of the TNF superfamily. The extracellular domain of CD30L contains two cysteine residues that is unique within the family and may form inter-subunit disulfide linkage. Even though CD30L contains the TNF-like extracellular domain, it is less clear if the protein is normally a dimer, trimer or a higher order oligomer. In addition, the biological function of the CD30L-CD30 axis in healthy individuals remains poorly understood as no human disease have been linked to defects along this axis.
As the CD30L expression is highly restricted to a small number of normal cells, its abundant expression in malignant cells seems to make it a good target for antibody therapy. Recently, CD30L was shown to be critical for the antigen-triggered proliferation and class switching of B lymphocytes. The observations that CD30L has diverse biological activity in different CD30-expressing cancers, ranging from enhancing survival to cell cycle arrest, make the CD30L-CD30 axis a less clear therapeutic target.
Nonetheless, a chimeric anti-CD30 antibody was reported to induce cell cycle arrest in Hodgkin-derived cell lines and is in a phase I study in patients with relapsed Hodgkin disease or CD30+ hematologic malignancies.
Amino Acid Sequence
1. Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, Sutherland GR, Brannan CI, Copeland NG, Jenkins NA, et al. (1993) CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349-1360.
2. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. (1994) Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83:2045–2056.
3. Wahl AF, Cerveny CH, Klussman K, et al. (2002) SGN-30, a chimeric antibody to CD30, for the treatment of Hodgkin’s disease. Proc Am Assoc Cancer Res. 43:4979a